Connor, Clark & Lunn Investment Management Ltd. Eton Pharmaceuticals, Inc. Transaction History
Connor, Clark & Lunn Investment Management Ltd.
- $21.1 Billion
- Q1 2025
A detailed history of Connor, Clark & Lunn Investment Management Ltd. transactions in Eton Pharmaceuticals, Inc. stock. As of the latest transaction made, Connor, Clark & Lunn Investment Management Ltd. holds 232,532 shares of ETON stock, worth $3.16 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
232,532
Previous 214,878
8.22%
Holding current value
$3.16 Million
Previous $2.83 Million
6.83%
% of portfolio
0.01%
Previous 0.01%
Shares
7 transactions
Others Institutions Holding ETON
# of Institutions
88Shares Held
14MCall Options Held
61.2KPut Options Held
33.1K-
Opaleye Management Inc. Boston, MA2.85MShares$38.8 Million10.18% of portfolio
-
Eco R1 Capital, LLC San Francisco, CA1.94MShares$26.4 Million1.98% of portfolio
-
Nantahala Capital Management, LLC New Canaan, CT1.18MShares$16 Million0.69% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.1MShares$15 Million0.0% of portfolio
-
Cannell Capital LLC Alta, WY691KShares$9.41 Million3.17% of portfolio
About Eton Pharmaceuticals, Inc.
- Ticker ETON
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 25,297,000
- Market Cap $344M
- Description
- Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing and commercializing pharmaceutical products for rare diseases. The company offers Biorphen, a phenylephrine injection for the treatment of clinically important hypotension resulting primarily from vasodilation in the setting of anesthesia; Carglumic Acid for th...